PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
TXG vs. DHR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between TXG and DHR is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.4

Performance

TXG vs. DHR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in 10x Genomics, Inc. (TXG) and Danaher Corporation (DHR). The values are adjusted to include any dividend payments, if applicable.

-30.00%-20.00%-10.00%0.00%10.00%20.00%30.00%AugustSeptemberOctoberNovemberDecember2025
-16.72%
-4.79%
TXG
DHR

Key characteristics

Sharpe Ratio

TXG:

-0.98

DHR:

0.30

Sortino Ratio

TXG:

-1.60

DHR:

0.60

Omega Ratio

TXG:

0.80

DHR:

1.07

Calmar Ratio

TXG:

-0.68

DHR:

0.29

Martin Ratio

TXG:

-1.19

DHR:

0.80

Ulcer Index

TXG:

53.69%

DHR:

8.27%

Daily Std Dev

TXG:

65.10%

DHR:

22.25%

Max Drawdown

TXG:

-93.49%

DHR:

-65.35%

Current Drawdown

TXG:

-92.55%

DHR:

-17.98%

Fundamentals

Market Cap

TXG:

$1.83B

DHR:

$174.72B

EPS

TXG:

-$1.52

DHR:

$5.22

Total Revenue (TTM)

TXG:

$445.76M

DHR:

$17.34B

Gross Profit (TTM)

TXG:

$308.86M

DHR:

$10.32B

EBITDA (TTM)

TXG:

-$96.17M

DHR:

$5.33B

Returns By Period

In the year-to-date period, TXG achieves a 5.01% return, which is significantly higher than DHR's 3.84% return.


TXG

YTD

5.01%

1M

7.41%

6M

-16.73%

1Y

-63.92%

5Y*

-30.42%

10Y*

N/A

DHR

YTD

3.84%

1M

4.41%

6M

-4.79%

1Y

3.61%

5Y*

10.91%

10Y*

21.43%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

TXG vs. DHR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TXG
The Risk-Adjusted Performance Rank of TXG is 77
Overall Rank
The Sharpe Ratio Rank of TXG is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of TXG is 44
Sortino Ratio Rank
The Omega Ratio Rank of TXG is 55
Omega Ratio Rank
The Calmar Ratio Rank of TXG is 88
Calmar Ratio Rank
The Martin Ratio Rank of TXG is 1515
Martin Ratio Rank

DHR
The Risk-Adjusted Performance Rank of DHR is 5353
Overall Rank
The Sharpe Ratio Rank of DHR is 5757
Sharpe Ratio Rank
The Sortino Ratio Rank of DHR is 4848
Sortino Ratio Rank
The Omega Ratio Rank of DHR is 4646
Omega Ratio Rank
The Calmar Ratio Rank of DHR is 5959
Calmar Ratio Rank
The Martin Ratio Rank of DHR is 5555
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

TXG vs. DHR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Danaher Corporation (DHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for TXG, currently valued at -0.98, compared to the broader market-2.000.002.004.00-0.980.30
The chart of Sortino ratio for TXG, currently valued at -1.60, compared to the broader market-4.00-2.000.002.004.006.00-1.600.60
The chart of Omega ratio for TXG, currently valued at 0.80, compared to the broader market0.501.001.502.000.801.07
The chart of Calmar ratio for TXG, currently valued at -0.68, compared to the broader market0.002.004.006.00-0.680.29
The chart of Martin ratio for TXG, currently valued at -1.19, compared to the broader market-10.000.0010.0020.0030.00-1.190.80
TXG
DHR

The current TXG Sharpe Ratio is -0.98, which is lower than the DHR Sharpe Ratio of 0.30. The chart below compares the historical Sharpe Ratios of TXG and DHR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.50AugustSeptemberOctoberNovemberDecember2025
-0.98
0.30
TXG
DHR

Dividends

TXG vs. DHR - Dividend Comparison

TXG has not paid dividends to shareholders, while DHR's dividend yield for the trailing twelve months is around 0.45%.


TTM20242023202220212020201920182017201620152014
TXG
10x Genomics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
DHR
Danaher Corporation
0.45%0.47%0.43%0.38%0.26%0.32%0.44%0.62%0.60%36.46%0.80%0.47%

Drawdowns

TXG vs. DHR - Drawdown Comparison

The maximum TXG drawdown since its inception was -93.49%, which is greater than DHR's maximum drawdown of -65.35%. Use the drawdown chart below to compare losses from any high point for TXG and DHR. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-92.55%
-17.98%
TXG
DHR

Volatility

TXG vs. DHR - Volatility Comparison

10x Genomics, Inc. (TXG) has a higher volatility of 16.13% compared to Danaher Corporation (DHR) at 5.28%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than DHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%AugustSeptemberOctoberNovemberDecember2025
16.13%
5.28%
TXG
DHR

Financials

TXG vs. DHR - Financials Comparison

This section allows you to compare key financial metrics between 10x Genomics, Inc. and Danaher Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab